Key Highlights
- Xcellbio installs new AVATAR Foundry system at Labcorp’s Ann Arbor site, expanding collaboration.
- Beta access program enables Labcorp to scale up from small to large-scale cell therapy manufacturing.
- Custom incubation technology enhances cell therapy potency and anti-tumor activity in challenging tumor microenvironments.
- Labcorp to support early-stage development of novel manufacturing techniques for cell and gene therapies.
Source: Business Wire
Notable Quotes
- “We are eager to scale our workflows with the new AVATAR Foundry instrument, which could allow us to support customers early in their development of novel manufacturing techniques for cell and gene therapies.” — Maryland Franklin, Ph.D., Vice President and Enterprise Head of Cell and Gene Therapy at Labcorp
- “Labcorp has long been one of Xcellbio’s closest collaborators, and we are pleased to include them as early members of our beta access program for the AVATAR Foundry.” — Brian Feth, CEO at Xcellbio
SoHC's Take
Xcellbio’s latest collaboration with Labcorp marks a significant step forward in scaling cell and gene therapy manufacturing. The introduction of the AVATAR Foundry system highlights Xcellbio’s ongoing commitment to advancing the potency and scalability of cell therapies, particularly in overcoming challenges related to the tumor microenvironment. This partnership not only accelerates innovation in cell therapy but also sets the stage for further breakthroughs in manufacturing techniques that can improve patient outcomes.
